Tempest Therapeutics Earnings Estimate

By analyzing Tempest Therapeutics' earnings estimates, investors can diagnose different trends across Tempest Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Tempest Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options. Tempest Therapeutics is projected to generate -0.36 in earnings per share on the 30th of September 2024. Tempest Therapeutics earnings estimates module stress-tests analyst consensus about projected Tempest Therapeutics EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Tempest Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Tempest Therapeutics' earnings estimates, investors can diagnose different trends across Tempest Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit Margin is likely to gain to 0.86 in 2024, whereas Gross Profit is likely to drop (400.1 K) in 2024. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.